Zodwa Dlamini is a Professor of Molecular Oncology and the founding Director and the Executive Head of the Pan African Cancer Research Institute (PACRI) in South Africa. She is the Director of South African Medical Research Council (SAMRC) Precision Oncology Research Unit (PORU). She is the DSI/NRF SARChI Chair in Precision Oncology and Cancer Prevention (POCP). She is a member of the American Association for Cancer Research (AACR) Advisory Group on Sub-Saharan Africa. She is a member of the AACR Pathology Resources in Africa Advisory Group. Professor Dlamini is a member of the African Organisation for Research and Training in Cancer (AORTIC) Research Committee Scientific Advisory Board. She is an elected member of the Academy of Science of South Africa. Professor Dlamini is an overseas Fellow of the Royal Society of Medicine (London). She is the Associate Editor for Frontiers in Oncology: Cancer Genetics Section

• 1. An Overview of Cervical Cancer, chemotherapy as treatment and resistance2. Current Treatment Options and Limitations of Cervical Cancer3. Radiotherapy treatment resistance in cervical cancer4. Mechanisms of Resistance in Cervical Cancer5. Reversal of Resistance Mechanisms in Cervical Cancer6. HPV and HIV-Associated epigenetics silencing in cervical cancer: Targets for overcoming chemoresistance7. Splicing-Associated Chemotherapy Resistance in cervical cancer: Targeting splicing signatures8. MicroRNAs involvement in cervical cancer chemotherapy drug resistance: restoring sensitivity to chemotherapy drugs9. Future Directions in Cervical Cancer Treatment10. Concluding Insights and Pathways to Overcome Cervical Chemoresistance

Zodwa Dlamini is a Professor of Molecular Oncology and the founding Director and the Executive Head of the Pan African Cancer Research Institute (PACRI) in South Africa. She is the Director of South African Medical Research Council (SAMRC) Precision Oncology Research Unit (PORU). She is the DSI/NRF SARChI Chair in Precision Oncology and Cancer Prevention (POCP). She is a member of the American Association for Cancer Research (AACR) Advisory Group on Sub-Saharan Africa. She is a member of the AACR Pathology Resources in Africa Advisory Group. Professor Dlamini is a member of the African Organisation for Research and Training in Cancer (AORTIC) Research Committee Scientific Advisory Board. She is an elected member of the Academy of Science of South Africa. Professor Dlamini is an overseas Fellow of the Royal Society of Medicine (London). She is the Associate Editor for Frontiers in Oncology: Cancer Genetics Section

• 1. An Overview of Cervical Cancer, chemotherapy as treatment and resistance2. Current Treatment Options and Limitations of Cervical Cancer3. Radiotherapy treatment resistance in cervical cancer4. Mechanisms of Resistance in Cervical Cancer5. Reversal of Resistance Mechanisms in Cervical Cancer6. HPV and HIV-Associated epigenetics silencing in cervical cancer: Targets for overcoming chemoresistance7. Splicing-Associated Chemotherapy Resistance in cervical cancer: Targeting splicing signatures8. MicroRNAs involvement in cervical cancer chemotherapy drug resistance: restoring sensitivity to chemotherapy drugs9. Future Directions in Cervical Cancer Treatment10. Concluding Insights and Pathways to Overcome Cervical Chemoresistance

Zodwa Dlamini is a Professor of Molecular Oncology and the founding Director and the Executive Head of the Pan African Cancer Research Institute (PACRI) in South Africa. She is the Director of South African Medical Research Council (SAMRC) Precision Oncology Research Unit (PORU). She is the DSI/NRF SARChI Chair in Precision Oncology and Cancer Prevention (POCP). She is a member of the American Association for Cancer Research (AACR) Advisory Group on Sub-Saharan Africa. She is a member of the AACR Pathology Resources in Africa Advisory Group. Professor Dlamini is a member of the African Organisation for Research and Training in Cancer (AORTIC) Research Committee Scientific Advisory Board. She is an elected member of the Academy of Science of South Africa. Professor Dlamini is an overseas Fellow of the Royal Society of Medicine (London). She is the Associate Editor for Frontiers in Oncology: Cancer Genetics Section

• 1. An Overview of Cervical Cancer, chemotherapy as treatment and resistance2. Current Treatment Options and Limitations of Cervical Cancer3. Radiotherapy treatment resistance in cervical cancer4. Mechanisms of Resistance in Cervical Cancer5. Reversal of Resistance Mechanisms in Cervical Cancer6. HPV and HIV-Associated epigenetics silencing in cervical cancer: Targets for overcoming chemoresistance7. Splicing-Associated Chemotherapy Resistance in cervical cancer: Targeting splicing signatures8. MicroRNAs involvement in cervical cancer chemotherapy drug resistance: restoring sensitivity to chemotherapy drugs9. Future Directions in Cervical Cancer Treatment10. Concluding Insights and Pathways to Overcome Cervical Chemoresistance